share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰製藥 | 144:擬議出售證券
美股SEC公告 ·  08/30 16:48

Moomoo AI 已提取核心訊息

Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 646 shares of common stock on 08/30/2024, with an aggregate market value of approximately $323,000. The shares were acquired on the same date through an option granted on 06/01/2018, and will be paid for in cash. This transaction follows a previous sale of 1,292 shares in the past three months, which had gross proceeds of $602,446.68. The planned sale is part of a trading plan adopted on 05/09/2024.
Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 646 shares of common stock on 08/30/2024, with an aggregate market value of approximately $323,000. The shares were acquired on the same date through an option granted on 06/01/2018, and will be paid for in cash. This transaction follows a previous sale of 1,292 shares in the past three months, which had gross proceeds of $602,446.68. The planned sale is part of a trading plan adopted on 05/09/2024.
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia計劃於08/30/2024出售646股普通股,估計市值約爲323,000美元。這些股份是在06/01/2018通過授予的期權獲得的,將以現金支付。此次交易是過去三個月內出售的1,292股股份的繼續,總收益爲602,446.68美元。計劃的銷售是在05/09/2024採取的交易計劃的一部分。
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia計劃於08/30/2024出售646股普通股,估計市值約爲323,000美元。這些股份是在06/01/2018通過授予的期權獲得的,將以現金支付。此次交易是過去三個月內出售的1,292股股份的繼續,總收益爲602,446.68美元。計劃的銷售是在05/09/2024採取的交易計劃的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息